Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyAetna Ruconest Precert Prior Auth Requirements | O…
    Ask Trek AI about this page
    CurrentAetnaPolicy N/A

    Ruconest (C1 esterase inhibitor, recombinant) Medication Precertification Request

    Customize your policy alerts

    Sign up for all Aetna policy alerts

    Know when Aetna releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is Aetna's precertification request form and instructions for Ruconest (C1 esterase inhibitor, recombinant) used for acute hereditary angioedema (HAE) and related indications; it governs what information providers must submit to request authorization for start or continuation of therapy.

    Policy Summary
    PayerAetna
    PolicyRuconest (C1 esterase inhibitor, recombinant) Medication Precertification Request
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionProviders must complete all fields on the 2-page precertification form and submit required clinical documentation for start or continuation requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2 pagesform length
    Multiple

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    diagnosis options
    Precert contactcontact
    Requiredclinical fields

    Coverage Criteria and Form Queries

    Precertification clinical criteria (informational form fields)

    Covered when the following documentation is provided on the precertification form and supports appropriate use:

    Required form elements: Completed patient, insurance, prescriber, dispensing/administration, product (Ruconest dose/frequency), diagnosis ICD codes, and signature/date must be provided.

    See form fields on pages 1-2 of the precertification request form.

    Diagnosis confirmation: Either: HAE with C1-INH deficiency/dysfunction confirmed by laboratory testing (low antigenic OR low functional C1-INH) OR HAE with normal C1-INH confirmed by laboratory testing or genetic testing, or meeting clinical criteria (angioedema refractory to high-dose antihistamine plus family history).C1-INH functional <50% or below lab lower limit; antihistamine trial: cetirizine 40 mg/day (or equivalent) for >= 1 month

    Form includes selectable checkboxes to document which diagnostic pathway applies.

    Prescriber specialty and use-case: Medication prescribed by or in consultation with a prescriber who specializes in the management of HAE AND intended for treatment of acute HAE attacks; form asks whether Ruconest will be used in combination with other acute HAE medications (e.g., Berinert, Firazyr, Kalbitor).

    For continuation requests, include documentation of reduction in severity/duration of attacks and rationale regarding prophylactic therapy consideration.

    The precertification form asks whether Ruconest will be used in combination with any other medication for acute hereditary angioedema (HAE) attacks (for example, Berinert, Firazyr, Kalbitor). Providers must disclose concurrent use of other acute HAE therapies on the form; this information is collected to inform the review but the form itself does not state that combination therapy is an automatic coverage exclusion.

    The plan may request additional information or clarification to evaluate a precertification request. If the requested supporting information is not provided or if a submission contains false or misleading information, the request may be denied and knowingly filing fraudulent information may result in criminal or civil penalties. Providers should respond promptly to any requests for clarification to avoid delays or adverse coverage determinations.

    Administration and Diagnosis Codes

    Administration codesCPT
    Administration code(s) (CPT)Administration CPT codes (specific codes to be provided by prescriber)
    Diagnosis codes (ICD-10)ICD-10
    Primary ICD CodePrimary diagnosis ICD code (to be specified)
    Secondary ICD CodeSecondary diagnosis ICD code (to be specified)
    Other ICD CodeOther diagnosis ICD code (to be specified)
    High‑dose antihistamine trial (inv-06) - key threshold
    Required trialCetirizine 40 mg per day (or equivalent) for at least one month
    IndicationApplied when angioedema is refractory to high‑dose antihistamine therapy and HAE with normal C1‑INH is being considered
    Duration thresholdMinimum trial duration: ≥1 month
    Equivalent agentsPolicy allows equivalent high‑dose antihistamine regimens (per clinician judgment) to meet the trial requirement

    Precertification and Submission Requirements

    Prior Authorization

    Obtain precertification and include start/last treatment date

    Precertification is required for either start of treatment or continuation of Ruconest; the precertification form includes selectable fields to indicate Start of treatment with Start date or Continuation of therapy with Date of last treatment. For continuation requests, include documentation showing reduction in attack severity and/or duration or rationale for ongoing therapy.

    • Check box for Start of treatment and provide Start date (form page 1).
    • Or check box for Continuation of therapy and provide Date of last treatment (form page 1).
    • Continuation requests must document reduction in severity and/or duration of acute attacks or provide rationale per continuation section.
    Step Therapy

    Document trial of high‑dose antihistamine when applicable

    When requesting Ruconest for HAE with normal C1-INH, the form asks whether angioedema was refractory to a trial of high‑dose antihistamine therapy (cetirizine 40 mg/day or equivalent) for at least one month as part of the diagnostic criteria.

    Drug Background

    Ruconest (C1 esterase inhibitor, recombinant) is a treatment for acute hereditary angioedema (HAE) attacks. The two‑page precertification request form must be completed in full when requesting start or continuation of therapy, including documentation of diagnosis (HAE subtype and relevant laboratory or genetic confirmation), whether the prescriber specializes in HAE management, concurrent acute HAE therapies if any, and for continuation requests evidence of clinical benefit. The form requires a signature and date and includes Aetna precertification contact information for follow‑up.

    HAE Diagnostic Definitions

    HAE with C1 inhibitor deficiency or dysfunction (inv-12) - lab criteria
    Laboratory criteriaC1‑INH antigenic level below the laboratory lower limit of normal
    Functional C1‑INHNormal antigenic level with low C1‑INH functional level (functional C1‑INH <50% or below the laboratory lower limit of normal)
    DocumentationLaboratory test results from the performing laboratory must be provided on the precertification form
    Diagnosis confirmationSelect when HAE with C1 inhibitor deficiency or dysfunction is confirmed by laboratory testing
    HAE with normal C1 inhibitor (inv-13) - confirmation examples
    Genetic confirmationPresence of pathogenic mutation on genetic testing (examples: F12, angiopoietin‑1, plasminogen, KNG1, HS3ST6, MYOF)
    Policy Summary
    PayerAetna
    PolicyRuconest (C1 esterase inhibitor, recombinant) Medication Precertification Request
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionProviders must complete all fields on the 2-page precertification form and submit required clinical documentation for start or continuation requests.
    SourceLink
    On This Page
    Coverage Criteria and Form QueriesAdministration and Diagnosis CodesPrecertification and Submission RequirementsDrug BackgroundHAE Diagnostic Definitions
    • Indicate whether angioedema was refractory to high‑dose antihistamine (cetirizine 40 mg/day or equivalent) for ≥1 month.
    Documentation Required

    Complete entire precertification form and include clinical documentation

    Complete all fields on the two‑page precertification form, including patient, insurance, prescriber, dispensing/administration, product (Ruconest dose and frequency), diagnosis ICD codes, required clinical information (HAE type, laboratory or genetic confirmation, prior therapies), and a signature with date.

    • Patient demographics and contact information (page 1).
    • Prescriber information including specialty, NPI and signature (prescriber section).
    • Dispensing/provider or administration setting and product dose/frequency.
    • Diagnosis ICD codes and required clinical fields confirming HAE subtype and prior therapy history.
    • Signature and date required on acknowledgement section.
    Denial Risk

    Avoid incomplete or fraudulent submissions — plan may request clarification

    The plan may request additional information or clarification to evaluate requests; knowingly filing materially false or fraudulent information is a crime and may lead to criminal and civil penalties.

    • Be prepared to provide supplemental documentation if requested by the plan.
    • Do not file requests with intent to defraud or conceal material information; fraudulent submissions are subject to penalties.
    Clinical criteria alternativeAngioedema refractory to high‑dose antihistamine trial plus family history may support diagnosis when genetic testing is not available
    DocumentationProvide laboratory or genetic test reports identifying the mutation or confirming normal C1‑INH with supporting results
    Selectable form optionForm includes a checkbox to indicate HAE with normal C1 inhibitor confirmed by laboratory or genetic testing